|
Name |
4-Hydroxy-3-methoxybenzamide
|
Molecular Formula | C8H9NO3 | |
IUPAC Name* |
4-hydroxy-3-methoxybenzamide
|
|
SMILES |
COC1=C(C=CC(=C1)C(=O)N)O
|
|
InChI |
InChI=1S/C8H9NO3/c1-12-7-4-5(8(9)11)2-3-6(7)10/h2-4,10H,1H3,(H2,9,11)
|
|
InChIKey |
TZZAKSLHHIJRLL-UHFFFAOYSA-N
|
|
Synonyms |
4-Hydroxy-3-methoxybenzamide; Vanillamide; 19072-58-3; Benzamide, 4-hydroxy-3-methoxy-; vanillylamide; ZI2G6PD23C; 4-hydroxy-3-methoxy-benzamide; NSC-604563; UNII-ZI2G6PD23C; NSC604563; NSC 604563; 3-Methoxy-4-hydroxybenzamide; SCHEMBL340398; 4-Hydroxy-3-methoxybenzamide #; DTXSID90172568; MB25472; Benzoic acid amide, 4-hydroxy-3-methoxy-; Q27295557
|
|
CAS | 19072-58-3 | |
PubChem CID | 354088 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 167.16 | ALogp: | 0.8 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 72.6 | Aromatic Rings: | 1 |
Heavy Atoms: | 12 | QED Weighted: | 0.687 |
Caco-2 Permeability: | -4.675 | MDCK Permeability: | 0.00001010 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.979 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.848 |
Blood-Brain-Barrier Penetration (BBB): | 0.955 | Plasma Protein Binding (PPB): | 66.96% |
Volume Distribution (VD): | 1.096 | Fu: | 43.63% |
CYP1A2-inhibitor: | 0.358 | CYP1A2-substrate: | 0.862 |
CYP2C19-inhibitor: | 0.044 | CYP2C19-substrate: | 0.064 |
CYP2C9-inhibitor: | 0.036 | CYP2C9-substrate: | 0.676 |
CYP2D6-inhibitor: | 0.052 | CYP2D6-substrate: | 0.435 |
CYP3A4-inhibitor: | 0.019 | CYP3A4-substrate: | 0.193 |
Clearance (CL): | 11.809 | Half-life (T1/2): | 0.721 |
hERG Blockers: | 0.066 | Human Hepatotoxicity (H-HT): | 0.053 |
Drug-inuced Liver Injury (DILI): | 0.437 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.035 | Maximum Recommended Daily Dose: | 0.016 |
Skin Sensitization: | 0.092 | Carcinogencity: | 0.46 |
Eye Corrosion: | 0.01 | Eye Irritation: | 0.926 |
Respiratory Toxicity: | 0.031 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001055 | 0.778 | D0E9CD | 0.442 | ||||
ENC000296 | 0.730 | D0C4YC | 0.386 | ||||
ENC000777 | 0.675 | D0U0OT | 0.385 | ||||
ENC000712 | 0.634 | D01WJL | 0.356 | ||||
ENC000172 | 0.553 | D0U5CE | 0.348 | ||||
ENC000068 | 0.550 | D0S2BT | 0.348 | ||||
ENC000325 | 0.532 | D03LGG | 0.348 | ||||
ENC001101 | 0.522 | D0BA6T | 0.340 | ||||
ENC000027 | 0.512 | D02XJY | 0.328 | ||||
ENC000095 | 0.477 | D08HVR | 0.327 |